Although the MIPS and MACRA rule is preliminary and subject to change, CMS is clearly putting a lot of weight into it, and the act will be a major part of oncology practice.
Robert "Bo" Gamble
Advertisement
Articles by Robert "Bo" Gamble
Advertisement
Latest Updated Articles
Don't Get Caught Behind the MACRA CurvePublished: September 22nd 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5